Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02948569 | Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome | PHASE1 | COMPLETED | 12 | — | — | Feb 1, 2017 | Jan 30, 2019 | May 4, 2025 | 1 | United States |
Subject undergoes a stable isotope infusion followed by blood draws. Plasma lipid samples are measured by gas chromatography/mass spectrophotometry.
| Arm | Type | Description |
|---|---|---|
| 3-V Bioscience-2640 | EXPERIMENTAL | Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days. |
| Name | Type | Description |
|---|---|---|
| 3-V Bioscience-2640 | DRUG | Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days. |
Inclusion Criteria: 1. Men with characteristics of metabolic syndrome 1. Waist circumference greater than 40 in (102 cm) 2. Plasma TG greater than 150 mg/dL 3. HDL cholesterol less than 40 mg/dL 4. Blood pressure greater than or equal to 130/85 mmHg 5. Fasting plasma glucose greater...